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Abstract
Background: A diverse range of factors influence clinicians' decisions regarding the allocation of
patients to different treatments for coronary artery disease in routine cardiology clinics. These
include demographic measures, risk factors, co-morbidities, measures of objective cardiac disease,
symptom reports and functional limitations. This study examined which of these factors
differentiated patients receiving angioplasty from medication; bypass surgery from medication; and
bypass surgery from angioplasty.
Methods: Univariate and multivariate logistic regression analyses were conducted on patient data
from 214 coronary artery disease patients who at the time of recruitment had been received a
clinical assessment and were reviewed by their cardiologist in order to determine the form of
treatment they were to undergo: 70 would receive/continue medication, 71 were to undergo
angioplasty and 73 were to undergo bypass surgery.
Results:  Analyses differentiating patients receiving angioplasty from medication produced 9
significant univariate predictors, of which 5 were also multivariately significant (left anterior
descending artery disease, previous coronary interventions, age, hypertension and frequency of
angina). The analyses differentiating patients receiving surgery from angioplasty produced 12
significant univariate predictors, of which 4 were multivariately significant (limitations in mobility
range, circumflex artery disease, previous coronary interventions and educational level). The
analyses differentiating patients receiving surgery from medication produced 14 significant
univariate predictors, of which 4 were multivariately significant (left anterior descending artery
disease, previous cerebral events, limitations in mobility range and circumflex artery disease).
Conclusion: Variables emphasised in clinical guidelines are clearly involved in coronary artery
disease treatment decisions. However, variables beyond these may also be important factors when
therapy decisions are undertaken thus their roles require further investigation.
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Background
Coronary artery disease (CAD) in the United Kingdom
accounted for over 117,000 deaths during 2002 and con-
tinues to represent a common cause of mortality in the UK
and in most developed societies [1]. Current management
options for CAD fall into three main categories, namely
medical therapy, percutaneous transluminal coronary
angioplasty with or without stenting, (PTCA) and coro-
nary artery bypass grafting (CABG). In the UK in the
National Health Service up to 45,000 PTCA and 28,500
CABG are conducted annually; each at a current average
cost of £2,609 (~$4,500) and £7,066 (~$12,000) respec-
tively [2]. Where detailed guidelines on the use of PTCA
and CABG have been proposed, they address a myriad of
precise individual scenarios and are considered extremely
complex [3-8]. Many parameters such as the variability of
symptoms and employment status are not addressed in
guidelines despite being considered to have an important
role in decision making and being routinely addressed by
clinicians. Rapid innovations in treatment often leave
guidelines struggling to keep pace with current practice. In
this context, the advent of minimally invasive options for
surgery, advanced percutaneous techniques and improved
medication regimens alter the risk benefit ratio and often
result in guidelines lagging behind with technological
advances that are already in clinical use.
A range of studies have reported that a not insignificant
proportion of PTCAs and, to a lesser degree, CABGs are
performed inappropriately or with uncertain appropriate-
ness [9-11]. These figures vary according to location (e.g.
US data indicates overuse of revascularization and UK
data its under use), the reference guidelines utilised and
the recency of the update of the guidelines. The allocation
of patients to particular therapies appears to be influenced
by a range of factors beyond guidelines and recommenda-
tions.
The aim of this paper was to examine the factors that
influence clinical decisions regarding the allocation of
patients to different treatments for coronary artery disease
in routine cardiology clinics. It was hypothesised that cli-
nicians would use both factors within guidelines as well as
those outside the guidelines. Separate analyses were con-
ducted to compare pairs of treatments from medication,
PTCA and CABG, to enable stepwise analyses to be con-
ducted that could determine the 'best' predictor variables.
It was expected that for the more disparate interventions
(e.g. medication and CABG), objective criteria would be
likely predictors of treatment choice; but when interven-
tions were less disparate (e.g. PTCA vs. CABG or medica-
tion vs. PTCA), variables beyond those in the guidelines
would be likely to exert a predictive influence.
Methods
Patient population
Between January 1999 and February 2001, 294 patients
with CAD from the caseloads of seven cardiologists, from
three National Health Service centres in London and sur-
rounding areas were selected as part of a convenience
sample. The participants were invited to take part in the
study in person or by mail. The patients were approached
after their cardiologist/consultant determined the form of
treatment they were to undergo, following a review of
clinical data (including angiograms) and patient consulta-
tions. The clinician determined whether the patients were
to start/continue medication or undergo revascularisation
by PTCA or CABG surgery. Two-hundred and fourteen
patients (72.79%) consented to take part in the study. The
response rate per treatment was similar, with 73.00% of
those about to undergo CABG, 74.74% of those about to
undergo PTCA and 70.71% of those to receive medication
consenting; with the resulting sample consisting of 70 in
receipt of medication, 71 to receive PTCA and 73 to
receive CABG surgery.
Measures
Objective disease measures (angiogram data) were
retrieved from patient medical records. Demographic,
medical history, subjective symptoms and functional lim-
itations data were obtained from patient self-reported
responses to a questionnaire pack collated for the study.
Demographic details included gender, age, employment
situation, and educational level (scored on a scale from 1
– no formal education after compulsory level, to 4 – grad-
uate/professional exams and above).
Previous cardiac history (previous interventions, previous
myocardial infarction), coronary risk factors (hypercho-
lesterolemia, hypertension, diabetes, smoking history and
family history for myocardial infarction, ischaemic heart
disease, stroke and neurological conditions) and co-mor-
bidities (arthritis/rheumatism, respiratory disease, renal
complications, cerebral events, gastrointestinal, periph-
eral vascular problems, thyroid problems and varicose
veins) were measured as binary yes/no responses, except
for smoking history which had three categories: never
smoked, ex-smoker and still smoking.
Symptom reports were elicited for angina, dyspnoea and
for a range of non-cardiac symptoms. Two items asked
patients the frequency with which they currently experi-
enced chest pains and shortness of breath. A further 31
items assessed a range of general symptoms (e.g. fatigue,
sleep difficulties, muscle pains, vomiting) from which an
average non-cardiac symptom-experience score was pro-
duced. Responses for all these items were recorded on a 4-
point scale, from all the time to never, with higher scores
representing greater frequency.BMC Cardiovascular Disorders 2006, 6:31 http://www.biomedcentral.com/1471-2261/6/31
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Scores for functional limitations due to cardiac symptoms
were collected through scales adapted from Feinstein rat-
ings [12]. These scales provided two scores relating to the
level of functional impairment resultant from (i) angina
and (ii) dyspnoea on the dimensions of task, pace and
daily functions. Averaged impairment scores ranged from
0 to 4; higher scores represented greater limitations.
Further health related functional disability scores were
obtained from the six subscales of the Sickness Impact
Profile-68 (SIP) [13]. The scales were: 'social behaviour'
(scores ranging from 0 to 12), 'mobility range' (0 to 10),
'emotional stability' (0 to 6),'somatic autonomy' (0 to
17), 'mobility control' (0 to 12) and 'psychological auton-
omy & communication' (0 to 11), with higher scores rep-
resenting greater limitations in daily functioning.
An objective measure of disease severity was obtained
from angiograms. These were analysed for the level of dis-
ease in three coronary disease prone arteries: the left ante-
rior descending, the circumflex and right coronary
arteries, each of which was rated on a four point scale (no
significant disease, mild, moderate or severe). Additional
measures of left ventricular function (no significant prob-
lems, mild, moderate or severe problems) and the
number of diseased arteries were recorded, providing a
total of five scores. These ratings were based on the agreed
ratings of two cardiologists.
The majority of patients (86.9% – 186/214) patients were
administered the questionnaires by one of the authors
(SPH) at the bedside or in home interviews. However due
to logistical reasons 5 medication and 23 PTCA patients
completed the questionnaires by themselves and posted
them back to the researchers.
Ethical approval for this study was granted by: Research
and Development Directorate of University College Lon-
don Hospital NHS Trust (ref: 99/0059) and the Clinical
Research, Education, Effectiveness and Development
Local Research and Ethics Committee of the Whittington
Hospital (ref: 99/05L).
Statistical analyses
The SPSS for Windows 11, LISREL 8.52 and SAS v8.2 sta-
tistical software packages were used for the analyses.
Preliminary examinations of the data revealed that the
overall level of missing data was 3.43% (279 scores from
8132 items). Nevertheless, sixty cases (28.04%) had data
missing on at least one variable, indicating that although
the overall level of missing data is low, its effects can be
relatively large. Missing values were imputed using the
Markov Chain Monte Carlo algorithm through LISREL
after finding no statistically reliable deviation from ran-
domness using Little's MCAR test: χ2 = 80.272, df = 96, p
= 0.876 (within SPSS 11). The remaining analyses were
conducted on the imputed data set [14,15].
Differences between treatment groups on each predictor
variable was tested using the χ2 test and one-way ANOVA's
(Brown-Forsythe test when unequal variances) with post
hoc Duncan's multiple range tests. Significance levels
were set at p < 0.01. Where appropriate, measures of the
strength of association between variables are provided
through omega squared (ω2) and Cramer's phi (φc), also
see Table 1.
Thereafter, three separate sets of logistic regression analy-
ses were conducted with the same analytic procedures. In
each analysis the likelihood of a particular treatment
option (response category) was compared to a less inva-
sive procedure (the reference category). The analyses per-
formed were: (i) PTCA vs. medication, (ii) CABG vs.
PTCA, and (iii) CABG vs. medication.
A series of univariate logistic analyses were conducted to
identify individually significant predictors of the response
treatment from the reference treatment in each of the
three analyses. The likelihood ratio criterion was
employed to test for the significance (p < 0.05) of each
predictor. Variables with p < 0.05 within the univariate
analyses were entered into a stepwise multivariate logistic
analysis, to identify independent predictors of treatment
type in each analysis. Significance was set at p < 0.01 in
these multivariate logistic regressions. Variables within
the regression equation were analyzed for removal at each
step, using a p > 0.05 significance level. The stepwise proc-
ess was halted when the residual chi-square was no longer
significant.
The final model was evaluated for, (i) goodness of fit
(deviance statistic), (ii) the association of predictor varia-
bles with the outcome variable (Nagelkerke's R2), (iii) suc-
cess in classification (% correctly classified cases,
sensitivity and specificity), and (iv) the discriminatory
power of the logistic equation (c statistic), see Table 1.
Individual parameters in each model are presented as
odds ratios for categorical data and p-deviance for contin-
uous variables. To aid interpretation, on occasions when
the odds ratio was less than one, its reciprocal was taken
and the finding interpreted in terms of the odds regarding
the reference group.
Results
Preliminary group differences
Demographic factors
The sample consisted of 175 males and 39 females, with
similar proportions of males and females in each treat-BMC Cardiovascular Disorders 2006, 6:31 http://www.biomedcentral.com/1471-2261/6/31
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ment group (CABG: 66 males, 7 females; PTCA: 57 males,
14 females; medication: 52 males, 18 females; χ2 = 6.394,
df = 2, p = 0.041; φc = 0.173). The mean age of the sample
was 64.1 years, with no age differences between treatment
groups (f(2,213)  = 2.588, p = 0.078; ω2  = 0.015). The
employment status of patients did not significantly differ
between groups (χ2 = 19.967, df = 12, p = 0.068; φc =
0.216). The PTCA participants were found to have a
higher educational level than the other two groups
(Brown-Forsythe, f(2,202.030) = 10.605, p < 0.001; ω2 =
0.082; PTCA mean = 2.51, medication mean = 1.97,
CABG mean score = 1.64).
Cardiac history, risk factors and co-morbidities
The three treatment groups were relatively similar with
regards co-morbidity, risk factors and cardiac history.
Only three variables differed significantly between the
groups. The medication group had the highest rate of cer-
ebral events (n = 12), followed by the PTCA (n = 7) then
the CABG (n = 1; χ2 = 10.526, df = 2, p = 0.005; φc =
0.222); however, the overall frequency of events was mod-
est. The PTCA group had more previous interventions
than the other two groups (χ2 = 27.779, df = 2, p < 0.001;
φc = 0.360), the majority of which were previous PTCA
(13/25 PTCA alone; 8/25 CABG alone; 4/25 PTCA and
CABG). Rates of family history of IHD also varied signifi-
cantly between groups (χ2 = 11.393, df = 2, p = 0.003; φc =
0.231). PTCA (n = 34) patients had lower rates than the
medication (n = 51) and CABG (n = 51) groups. Rates of
other conditions were similar between treatments groups,
and the common risk factors for CAD did not significantly
differ between groups.
Angiogram reports
Objective disease scores revealed significant treatment
group effects (p < 0.01) for all indices except right coro-
nary artery disease (f(2,111) = 4.319, p = 0.015; ω2 = 0.030).
LAD artery disease (Brown-Forsythe, f(2,184.061) = 31.712, p
< 0.001; ω2 = 0.223), significantly differed between medi-
cation and the two revascularisation groups. Circumflex
artery scores (Brown-Forsythe, f(2,201.629) = 19.785, p <
0.001; ω2 = 0.149), total vessels diseased scores (Brown-
Forsythe, f(2,183.301) = 6.525, p = 0.002; ω2 = 0.049), and
ventricular function scores (Brown-Forsythe, f(2,183.046) =
8.533, p < 0.001; ω2 = 0.066), all produced a pattern of
group differences where the medication and PTCA groups
significantly differing from the CABG group but not from
each other. Group mean scores are shown in Table 2.
Cardiac symptoms and associated functional limitations
Significant treatment group differences were found on the
angina frequency scores, (f(2,211) = 5.444, p = 0.005; ω2 =
0.040). Post hoc tests revealed the medication group to
have significantly less frequent angina than the PTCA and
CABG groups. The frequency of shortness of breath did
not significantly vary between treatment groups (f(2,211) =
1.562, p = 0.212; ω2 = 0.005); nor did the level of non-car-
diac symptoms (f(2,211) = 1.640, p = 0.196; ω2 = 0.006).
Table 1: Criteria for statistical interpretation
Statistic Interpretation
Strength of association ω2 ≈ 0.01 small association
≈ 0.06 medium association
≈ 0.14 large association
φc < 0.3 little or no association
0.3 to 0.7 weak association
0.7 to 1.0 strong association
Regression model evaluation deviance statistic - significance of unexplained (residual) variance in the dependent variable; 
thus is desired to be non-significant
Nagelkerke's R2 - the association between predictor variables and the outcome variable. 
Statistic ranges from 0 to 1 with higher scores indicating stronger 
associations.
% of correctly classified cases - calculated at the start of the procedure and at the end of the analysis 
using the cut-off point of 0.5 for the estimated probability of the 
outcome variable
sensitivity - the proportion of true positives or the proportion of cases correctly 
identified by the test as meeting the response category
specificity - the proportion of true negatives or the proportion of cases correctly 
identified by the test as meeting the reference category
c statistic - varies from 0.5 (the models predictions are no better than chance) to 1 
(the model always assigns the higher probabilities to correct cases than 
incorrect ones)BMC Cardiovascular Disorders 2006, 6:31 http://www.biomedcentral.com/1471-2261/6/31
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One-way ANOVAs of the functional limitations associ-
ated with cardiac symptoms, revealed that the ratings for
angina were significantly different between treatment
groups (Brown-Forsythe, f(2,204.159) = 9.618, p < 0.001; ω2
= 0.075), but not for dyspnoea (Brown-Forsythe,
f(2,201.311) = 4.474, p = 0.013; ω2 = 0.031). The post hoc
tests for angina ratings showed the medication group was
significantly less functionally impaired by angina than
both the PTCA and CABG patients.
Activities of daily living
On limitations in activities of daily living, the groups dif-
fered significantly on two indices, social behaviour
(f(2,211) = 5.398, p = 0.005; ω2 = 0.039) and mobility range
(Brown-Forsythe, f(2,185.686) = 33.072, p < 0.001; ω2 =
0.231). In both cases, the medication and PTCA groups
were significantly different from the CABG group but not
from each other. The other activity indices revealed simi-
lar group scores: Emotional Stability, (Brown-Forsythe,
f(2,197.489) = 2.211, p = 0.112; ω2 = 0.011); Somatic Auton-
omy, (f(2,211) = 1.612, p = 0.200; ω2 = 0.006); Mobility
Control, (f(2,211) = 1.963, p = 0.143; ω2 = 0.009); and Psy-
chological Autonomy and Communication, (f(2,211)  =
0.490, p = 0.613; ω2 = 0.000).
Predictors of treatment group
The univariate analyses (Table 3) were followed by the
same comparisons in a multivariate analysis (Table 4).
The results of both sets of analyses are collated and sum-
marised in Table 5.
Analyses I: PTCA compared to medication
In the univariate analysis, nine of the predictor variables
produced significant findings (see Table 3a). Increasing
age, hypertension and a family history of ischemic heart
disease (IHD) reduced the odds of a patient receiving
PTCA. Educational level, previous interventions, angina
and dyspnoea related functional limitations, angina fre-
quency and LAD disease, increased the odds of PTCA.
Within the multivariate analysis (Table 4a), LAD artery
disease, previous intervention, age, hypertension and
angina frequency were included in the final model. The
overall model produces a satisfactory goodness of fit, with
non-significant residual variance (deviance = 135.184, df
Table 2: Demographics, angiogram scores, symptom reports and functional ability by treatment group
Total Medicati
on
PTCA CABG p
214 70 71 73
Gender Male 175 52 57 66
Female 39 18 14 7 0.041
Age Mean 64.09 66.00 62.03 64.26 0.078
Education level Mean 2.04 1. 97a 2.51b 1.64a <0.001
Angiogram scores LAD artery disease 2.18 1.56a 2.31b 2.64b <0.001
Circumflex artery disease 1.67 1.30a 1.39a 2.30b <0.001
RCA disease 1.98 1.80 1.85 2.27 0.015
Number of disease vessels 2.51 2.39a 2.37a 2.77b 0.002
Ventricular Function score 0.63 0.56a 0.39a 0.93b <0.001
Symptom frequency Angina 2.03 1.80a 2.18b 2.11b 0.005
Dyspnoea 2.22 2.19 2.37 2.11 0.212
Non-cardiac 1.43 1.38 1.46 1.46 0.196
Functional limitations Angina associated 1.80 1.29a 1.93b 2.15b <0.001
Dyspnoea associated 1.56 1.21 1.67 1.79 0.013
Activities of daily living Social Behaviour 4.43 3.96a 3.97a 5.32b 0.005
Emotional Stability 1.30 1.43 1.48 1.00 0.112
Mobility Range 1.91 1.00a 1.15a 3.52b <0.001
Somatic Autonomy 0.84 0.94 0.58 0.99 0.200
Mobility Control 4.00 3.81 3.63 4.53 0.143
Psychological Autonomy & Communication 1.71 1.89 1.75 1.51 0.613
Gender analyses conducted with Chi-sq test, remainder with ANOVAs.
Significant treatment group differences revealed within the ANOVAs are indicated with different superscript letters.BMC Cardiovascular Disorders 2006, 6:31 http://www.biomedcentral.com/1471-2261/6/31
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= 135, p = 0.479). Nagelkerke's R2 = 0.464, indicated the
predictor variables were associated reasonably well with
the outcome variable. Correct classification of cases
moved from 50.4% to 70.2% in the final model, with
71.8% of PTCA patients (i.e. sensitivity) and 68.6% of
medication patients correctly classified (i.e. specificity).
The discriminatory power of the model is fairly strong
with the c-statistic at 0.849.
Examination of parameter estimates for categorical pre-
dictors in this model indicated that holding other varia-
bles constant, (i) having had a previous cardiac
intervention increased the odds of PTCA by ≈ 9 times, and
(ii) hypertension increased the odds of being in the med-
ication group by ≈ 4 times. On the continuous predictors,
the odds of being a medication patient increased by ≈ 7%
for each years increase in age. In this instance, an incre-
ment of 10 years in age doubled the odds of being in the
medication as opposed to PTCA group. Unsurprisingly,
greater angina frequency and LAD artery disease both
increased the odds of having PTCA. Thus going from 'occa-
sional' angina to 'frequent' angina increased the odds of
PTCA by 2.4 times and going from 'mild' to 'moderate' lev-
Table 3: Variables that achieved significance in the univariate comparisons between treatment groups
VARIABLES Likelihood ratio Exp (β) Confidence interval RATES/MEAN SCORES
Model change df. Sig. Odds Ratio Lower bound Upper bound Reference Response
(a) PTCA from Medication Medication PTCA
Increasing age 4.644 1 0.031 0.967 0.928 1.008 66.00 62.03
Higher educational attainment 6.887 1 0.009 1.447 0.999 2.096 1.97 2.51
Previous intervention 20.517 1 < 0.001 8.961 2.055 39.067 4 25
Hypertension 4.505 1 0.034 0.482 0.197 1.178 36 24
Family history: IHD 9.306 1 0.002 0.342 0.136 0.863 51 34
LAD artery disease 21.166 1 < 0.001 2.328 1.392 3.893 1.56 2.31
Angina frequency 11.204 1 0.001 2.351 1.182 4.677 1.80 2.18
Angina functional limitations 11.079 1 0.001 1.651 1.102 2.474 1.29 1.93
Dyspnoea functional limitations 5.851 1 0.016 1.444 0.968 2.153 1.21 1.67
(b) CABG from PTCA PTCA CABG
Higher educational attainment 19.186 1 < 0.001 0.525 0.350 0.786 2.51 1.64
Previous intervention 16.410 1 < 0.001 0.165 0.046 0.587 25 6
Family history: IHD 7.251 1 0.007 2.523 1.028 6.192 34 51
Family history: Neurological 5.400 1 0.020 0.194 0.025 1.527 9 2
Cerebral events 5.505 1 0.019 0.127 0.008 2.065 7 1
LAD artery disease 6.996 1 0.008 1.834 0.980 3.435 2.31 2.64
Circumflex artery disease 22.489 1 < 0.001 2.058 1.352 3.132 1.39 2.30
RCA disease 5.600 1 0.018 1.444 0.960 2.173 1.85 2.27
Number of vessels diseased 12.709 1 < 0.001 2.546 1.221 5.310 2.37 2.77
Ventricular disease 12.979 1 < 0.001 2.037 1.172 3.540 0.39 0.93
SIP: Social behaviour 7.937 1 0.005 1.182 1.010 1.382 3.97 5.32
SIP: Mobility range 35.312 1 < 0.001 1.608 1.254 2.062 1.15 3.52
(c) CABG from Medication Medication CABG
Gender 6.612 1 0.010 0.306 0.088 1.062 18 7
Hypercholesterolemia 6.892 1 0.009 0.410 0.169 0.994 45 31
Hypertension 6.773 1 0.009 0.407 0.166 1.003 36 22
Cerebral events 12.419 1 < 0.001 0.067 0.004 1.018 12 1
LAD artery disease 54.350 1 < 0.001 5.396 2.553 11.407 1.56 2.64
Circumflex artery disease 32.294 1 < 0.001 2.647 1.617 4.333 1.30 2.30
RCA disease 7.800 1 0.005 1.599 1.024 2.495 1.80 2.27
Number of vessels diseased 9.668 1 0.002 2.116 1.080 4.144 2.39 2.77
Ventricular disease 7.173 1 0.007 1.737 0.998 3.023 0.56 0.93
Angina frequency 5.824 1 0.016 1.710 0.949 3.080 1.80 2.11
Angina functional limitations 15.130 1 < 0.001 1.660 1.168 2.358 1.29 2.15
Dyspnoea functional limitations 7.619 1 0.006 1.450 1.015 2.072 1.21 1.79
SIP: Social behaviour 7.714 1 0.005 1.175 1.008 1.371 3.96 5.32
SIP: Mobility range 40.346 1 < 0.001 1.683 1.299 2.181 1.00 3.52BMC Cardiovascular Disorders 2006, 6:31 http://www.biomedcentral.com/1471-2261/6/31
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els of LAD artery disease increased the odds of PTCA by
2.6 times.
Analyses II: CABG compared to PTCA
Univariate analyses identified twelve variables as signifi-
cant predictors of CABG treatment as opposed to PTCA
(see Table 3b). A higher level of education, having
received previous cardiac interventions, family history of
neurological conditions and previous cerebral events were
all associated with lowered odds of receiving CABG.
Higher scores on the five indices from the angiogram, a
family history of IHD and reduced levels of social behav-
iour and mobility range (SIP-68) resulted in greater odds
of CABG. Four of these univariate predictors were retained
in the final stepwise multivariate model: education level,
previous cardiac intervention, circumflex artery disease
and mobility range (see Table 4b). This model was satis-
factory with regards to overall model fit, with non-signifi-
cant residual variance (deviance = 118.363, df = 138 p =
0.885), and Nagelkerke's R2 at 57.5%. Classification of
cases moved from 50.7% to 78.5% correct in the final
model; 78.1% of CABG patients and 78.9% of PTCA
patients were correctly classified. The discriminatory
power of the logistic equation was relatively good (c =
0.892).
The individual parameter estimates indicated that the
odds for PTCA increased by ≈12 times if a previous inter-
vention had been undertaken. The continuous predictors
revealed that a unit increase in educational level (e.g.
going from A-level to graduate standard) almost halved
the odds of being in the CABG group. A single additional
score on the functional limitation on the SIP mobility
range scale increased the odds of CABG by 60% and mov-
ing from 'mild' to 'moderate' levels of circumflex artery dis-
ease increased the odds of CABG by ≈ 2 times.
Table 4: Multivariate analysis comparing pairs of treatment groups
Analysis of maximum likelihood estimates odds ratio/p-deviance
Parameter Entry df estimate std. error Wald χ2 Pr > chi square std. estimate point estimate 99% Wald CI 99% Wald CI
(a) Medication vs. 
PTCA
Constant 0 1 1.131 1.454 0.606 0.437 .
LAD artery 
disease
1 1 0.970 0.240 16.374 < 0.001 0.536 2.639 1.423 4.894
Previous 
intervention
2 1 1.093 0.322 11.536 0.001 . 8.896 1.696 46.675
Increasing age 3 1 -0.065 0.021 9.364 0.002 -0.397 0.937 0.887 0.990
Hypertension 4 1 -0.664 0.229 8.373 0.004 . 0.265 0.081 0.864
Angina 
frequency
5 1 0.883 0.341 6.694 0.010 0.337 2.418 1.004 5.822
(b) PTCA vs. 
CABG
Intercept 0 1 -1.889 0.710 7.091 0.008 .
SIP: Mobility 
range
1 1 0.475 0.112 17.868 < 0.001 0.667 1.607 1.204 2.147
Circumflex 
artery disease
2 1 0.756 0.215 12.345 < 0.001 0.490 2.128 1.223 3.704
Previous 
intervention
3 1 -1.246 0.337 13.674 < 0.001 . 0.083 0.015 0.469
Higher 
educational 
attainment
4 1 -0.661 0.204 10.545 0.001 -0.441 0.516 0.305 0.872
(c) Medication vs. 
CABG
Intercept 0 1 -8.831 1.548 32.561 < 0.001 .
LAD artery 
disease
1 1 1.616 0.373 18.804 < 0.001 0.853 5.034 1.927 13.150
Previous 
cerebral events
2 1 -2.463 0.707 12.127 0.001 . 0.007 0.000 0.277
SIP: Mobility 
range
3 1 0.620 0.162 14.761 < 0.001 0.870 1.859 1.227 2.818
Circumflex 
artery disease
4 1 1.095 0.293 13.991 < 0.001 0.661 2.991 1.406 6.359BMC Cardiovascular Disorders 2006, 6:31 http://www.biomedcentral.com/1471-2261/6/31
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Analyses III: CABG compared to medication
Fourteen predictors, listed in Table 3c, were significant in
the univariate analyses. Increasing severity within all the
angiogram and function related scores significantly
increased the likelihood of receiving a CABG. The pres-
ence of co-morbidities (hypercholesterolemia, hyperten-
sion and previous cerebral events) and being female
individually reduced the likelihood of CABG.
The multivariate stepwise analysis of these predictors indi-
cated relatively little residual variance (deviance = 85.691,
df = 138, p = 0.999), a high association between the DV
and the predictors (Nagelkerke's R2 = 0.726), and a large
proportion of correctly classified cases (84.6%, up from
51.0% in the constant only model; sensitivity = 84.9%;
specificity = 84.3%). The discriminatory power of the
logistic regression equation was the highest of the three
sets (c = 0.944).
Having previous cerebral events increased the odds of
receiving medication treatment by 142.9 times, (see Table
4c). On the continuous measures, the odds of CABG were
≈ 5 times higher with a one unit increase in LAD artery dis-
ease and ≈ 3 times higher with unit increases in circumflex
artery disease severity. Greater mobility range limitations
increased the odds of CABG by ≈ 2 times per unit increase.
Discussion
This study examined factors that influenced the allocation
of patients to different treatments for CAD. Three sets of
analyses were conducted comparing actual decisions to
undergo: PTCA rather than receive medication, CABG
rather than PTCA, and CABG rather than medication.
Univariate analyses revealed a wide range of differentiat-
ing factors including, demographic variables, co-morbidi-
ties, family histories, symptom reports, functional
limitations and angiogram indices (i.e. objective disease
reports). While many of these factors are in the treatment
guidelines (e.g. co-morbidities, angiogram indices); oth-
ers are not (e.g. educational level, patient rated function-
ing or symptom reports), but appear to be, on empirical
analysis, implicitly involved in the decision processes,
particularly in analyses involving comparisons with
PTCA. This indicates that clinicians are undoubtedly
aware that multiple factors outside of those explicitly dis-
cussed in guidelines (which are usually technical and clin-
ical in nature), should be addressed and guide decision
making about treatment modality.
Gender has long been a controversial issue in CAD and
much evidence has accumulated regarding poorer out-
comes for women [16]. Research investigating, gender dif-
ferences in patients undergoing evaluation for CAD has
found contradictory results but generally suggested that
resource utilisation may be lower in women [17-19]. In a
large study, Miller et al. [20] did find less coronary angi-
ographies performed in women being assessed for CAD
and lower referral for revascularisation in univariate anal-
ysis. Although, in this study, females were almost 70% less
likely than males to have CABG when compared to medi-
cation, this effect was not robust enough to be retained in
the multivariate analysis, suggesting that gender is not a
primary concern during this decision process, between the
two most disparate treatments. Further, in the other anal-
yses there was no evidence to suggest a bias for males to
receive particular interventions. However, these findings
must be interpreted in light of the small number of female
participants, which may limit the power to find gender
effects.
Previous research has shown that mortality increases with
age in both CABG and PTCA [21,22]. In the present study
age was not a significant factor in determining CABG from
the other two treatments. The CABG results were unex-
pected but the increased risks may have been counter-bal-
anced by judgements regarding graft patency and life
expectancy. In contrast, an increase of ten years in age
nearly doubled the likelihood of medication over PTCA in
the multivariate analysis. While this may reflect a natural
tendency to perform less invasive procedures in the eld-
erly, it is also important that the PTCA group had signifi-
cantly higher levels of education in comparison to both
medication and CABG groups. One may speculate that the
younger more educated individuals may be both more
aware of and willing to try newer treatments and possibly
more actively involved in their treatment decisions. It is
however important that the PTCA group were also distin-
guished by their greater experience of CAD treatments and
possible vicarious knowledge/experience from family
members who had a history of IHD. PTCA patients were
more likely to have received a previous intervention
(mainly PTCA's) than both the medication and CABG
patients in both the univariate and multivariate analyses.
Given the relatively high rates of restenosis following
PTCA, this finding is not unexpected. The previous experi-
ences may have provided patients with clearer expecta-
tions upon which to base and participate in the decisions
regarding their treatment.
Variables concerning patient history and co-morbidities
appeared to appropriately reduce the likelihood of the
more interventional treatments. Hypertension had a ten-
dency to increase the odds of remaining on/starting med-
ication. In the PTCA versus medication analysis, this effect
was retained in the multivariate analysis. Hypercholester-
olemia reduced the likelihood of CABG as opposed to
medication, and the effects of a family history of neuro-
logical problems reduced the likelihood of CABG from
PTCA. Less obviously a family history of IHD, reduced theBMC Cardiovascular Disorders 2006, 6:31 http://www.biomedcentral.com/1471-2261/6/31
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Table 5: Summary findings of univariate and multivariate significant effects
Univariate PTCA from Medication CABG from PTCA CABG from Medication
Increasing age ▼
Gender ▼
Higher educational attainment ▲▼
mployment
Previous coronary intervention ▲▼
Hypercholesterolemia ▼
Hypertension ▼▼
Previous MI
Diabetes
Smoking history
Family history: IHD ▼▲
Family history: Neurological ▼
Family history: MI
Family history: Stroke
Previous cerebral events ▼▼
Arthritis/Rheumatism
Respiratory
Renal complications
GI tract problems
Peripheral vascular disease
Thyroid problems
Varicose veins
LAD artery disease ▲▲▲
Circumflex artery disease ▲▲
RCA disease ▲▲
Number of vessels diseased ▲▲
Ventricular disease ▲▲
Angina frequency ▲▲
Dyspnoea frequency
Non-cardiac symptoms
Angina functional limitations ▲▲
Dyspnoea functional limitations ▲▲
SIP: Social behaviour ▲▲
SIP: Mobility range ▲▲
SIP: Emotional stability
SIP: Somatic autonomy
SIP: Mobility control
Multivariate PTCA from Medication – 5 CABG from PTCA – 4 CABG from Medication – 4
Increasing age ▼3
Higher educational attainment ▼4
Previous coronary intervention ▲2 ▼3
Hypertension ▼4
Previous cerebral events ▼2
LAD artery disease ▲1 ▲1
Circumflex artery disease ▲2 ▲4
Angina frequency ▲5
SIP: Mobility range ▲1 ▲3
▲ = increase in odds; ▼ = decrease in odds; numerals indicate order of entry during the stepwise procedureBMC Cardiovascular Disorders 2006, 6:31 http://www.biomedcentral.com/1471-2261/6/31
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odds of PTCA when compared to both medication and
CABG. However, none of these findings were retained in
the multivariate analyses.
The measures from the angiogram reports demonstrated a
strikingly consistent effect in predicting the likelihood of
CABG, as would be expected and is supportive of the
guidelines. Within the univariate analysis, all five of the
measures (levels of LAD, circumflex and right coronary
artery disease, the number of disease arteries and the level
of ventricular disease) increased the likelihood of CABG.
The per unit increase in these measures led to a multipli-
cation in odds of CABG ranging from 1.6 to 5.4 times in
the medication versus CABG analyses, and between 1.5
and 2.5 times for the PTCA versus CABG analysis. For the
most part, the odds ratios determining CABG from medi-
cation were larger than those determining CABG from
PTCA, as would be expected. The other significant result
from the univariate analyses of the angiogram data
showed that increasing LAD artery disease predicts a
greater likelihood of PTCA from medication; a finding
consistent with treatment guidelines.
The multivariate analyses helped determine which of the
angiogram measures was the most relevant to the treat-
ment decision process. The pattern of results indicated
that with increased LAD disease, medication was not con-
sidered a sufficient treatment; the likelihood of PTCA or
CABG was increased. Moving from mild to moderate LAD
disease increased the odds of PTCA from medication by ≈
2.6 times, and the odds of CABG from medication by
approximately twice this (5 times). Increasing LAD dis-
ease did not significantly alter the odds of CABG in com-
parison to PTCA.
Increasing levels of disease in the circumflex artery
increased the likelihood that CABG would be the chosen
option. A move from mild to moderate levels of circum-
flex artery disease more than doubled the odds of CABG
from PTCA and almost trebled the odds of CABG as
opposed to medication. Interestingly, the number of dis-
eased arteries, which is often an indication for CABG
rather than PTCA [6], was not retained in the multivariate
model. These results are reassuring in that they confirm
the important role of the angiogram reports when decid-
ing whether to proceed with interventional strategies, in
particular CABG.
Patient reports of the frequency of their symptoms, and
the manner in which their poor health is affecting their
lives, are the customary way in which patients present the
condition to their health care professionals. High levels of
angina symptom reports and greater functional limita-
tions increased the likelihood of receiving either of the
two more invasive procedures. They did not, however, sig-
nificantly affect the decision between PTCA and CABG.
The symptom reports that appeared to drive the decisions
were specific and non-cardiac symptoms did not affect the
treatment decision. In the multivariate analysis, the fre-
quency of angina was retained when comparing PTCA to
medication, such that moving from occasional to frequent
angina increased the odds of PTCA by ≈ 2.4 times. The
finding that only one symptom measure entered each
multivariate analysis is likely to be due to the degree of
correlation between the various symptom report meas-
ures (range from 0.731 to 0.225 all p < 0.001).
Reports of restrictions on activities of daily living were
also found to influence treatment decisions. Specifically,
greater limitations in social behaviours and mobility
increased the likelihood of receiving CABG, from both
PTCA and medication. When entered into the multivari-
ate analysis, the illnesses effect on mobility was the only
measure of activities of daily living that was retained;
increasing the odds of CABG from medication and PTCA
by 80% and 60% respectively, for a unit increase in mobil-
ity range problems. This suggests that mobility restrictions
are an important trigger to provoke more invasive treat-
ments by cardiologists.
Overall each category of information was represented
within the multivariate analyses, although all the catego-
ries were not represented in each of the analyses. This sug-
gests that all types of information are being considered
during the decision processes, although some may only be
evident when examined within specific treatment com-
parisons. Two distinct patterns of outcomes can be dis-
cerned from the cumulative results of the three sets of
analyses. First, the increased likelihood of CABG was pri-
marily based on reports of greater objective disease (angi-
ograms) and functional limitations. Second, the data
suggests that decisions concerning PTCA can be inter-
preted to be driven by patient characteristics which may
reflect the influence of patient preferences although these
were not directly measured in this study. The findings
reveal that treatment decisions are subject to a range of
different influences and not simply guided by protocols.
It must be noted that treatment modalities/technologies
and the guiding protocols are changing constantly. The
management of coronary disease has changed over the
period since the participants for this study were recruited
(e.g. as many as three times more percutaneous coronary
interventions are now done in the UK). However,
although the manner in which factors are addressed in
allocating patients to treatments modalities during the
decision making process has altered in guidelines, the spe-
cific factors that are considered have not changed signifi-
cantly in the recent updates [4,6].BMC Cardiovascular Disorders 2006, 6:31 http://www.biomedcentral.com/1471-2261/6/31
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Potential limitations to this study include the relatively
small sample of participants, which were predominately
male and drawn from a limited geographical region, taken
from a small pool of cardiologists; resulting in a highly
selective patient population (with low incidences of some
co-morbidities). Each of these factors may limit the gener-
alisability of results (e.g. the small number of female par-
ticipants may have precluded finding significant gender
effects). A larger multi-centre study, with stratified sam-
pling may help to resolve some of these issues, and it is
acknowledged that both geographical and individual con-
sultant factors may confound treatment decisions. For
instance there may be a proclivity to perform interven-
tional cardiology in certain regions and/or that individual
cardiologists may be referred particular patients, and have
preferences for particular treatments [23]. More detailed
analysis of such factors with a larger study sample may
help to unravel how such factors confound treatment
decision processes.
Additionally, a limitation of observational studies, such as
the current one, is that they cannot exclude as explana-
tions other unmeasured factors [11]. It may be necessary
to conduct further studies to see how recent changes in
treatment and technology effects decision making. This
study provides both a basis for this and evidence that
treatment decisions are subject to a range of different
influences including those in protocols.
Conclusion
Although there are a number of clinical guidelines for
deciding between the treatments available for CAD, this
study shows that variables beyond those in these proto-
cols, such as patient reports of disability and patient char-
acteristics, may also be important variables when therapy
decisions are undertaken. The role of these factors and
their relationship and interactions with factors empha-
sised in the guidelines require further investigation to
delineate the processes involved in treatment decisions
for CAD.
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